Neoadjuvant immunotarget therapy in patients with locally advanced oral squamous cell carcinoma: report of 2 cases and literature review

doi:10.19438/j.cjoms.2022.04.018

Abstract

Abstract: Neoadjuvant therapy is systemic therapy before local treatment in patients with non-distant metastatic malignancies, aiming to reduce tumor load and distant metastasis, increase opportunity of radical resection, and relieve symptoms, et al. In this report, we presented two patients with locally advanced oral squamous cell carcinoma, who were treated with camrelizumab and apatinib as neoadjuvant therapy in Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, and reviewed and discussed the relevant literatures.

Key words: Oral squamous cell carcinoma, Neoadjuvant therapy, Multidisciplinary team

CLC Number:

R739.8

ZHANG Yi-yi, YANG Yue-yi, JU Wu-tong, ZHONG Lai-ping. Neoadjuvant immunotarget therapy in patients with locally advanced oral squamous cell carcinoma: report of 2 cases and literature review[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(4): 413-416.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Leemans CR, Snijders PJF, Brakenhoff RH.The molecular landscape of head and neck cancer[J]. Nat Rev Cancer, 2018, 18(5): 269-282.
[3] 郭海鹏, 刘木元, 杨熙鸿, 等. 新辅助化疗对口腔癌生存率影响的Meta分析[J]. 汕头大学医学院学报, 2014, 27(02): 100-103.
Guo HP, Liu MY, Yang XH, et al.Meta analysis of survival effect in patients with oral carcinoma receiving neoadjuvant chemotherapy[J]. Journal of Shantou University Medical College, 2014, 27(2): 100-103.
[4] Hill BT, Price LA.Lack of survival advantage in patients with advanced squamous cell carcinomas of the oral cavity receiving neoadjuvant chemotherapy prior to local therapy, despite achieving an initial high clinical complete remission rate[J]. Am J Clin Oncol, 1994, 17(1): 1-5.
[5] Hill BT, Price LA, MacRae K. Importance of primary site in assessing chemotherapy response and 7-year survival data in advanced squamous-cell carcinomas of the head and neck treated with initial combination chemotherapy without cisplatin[J]. J Clin Oncol, 1986, 4(9): 1340-1347.
[6] Abdel-Wahab M, Abitbol A, Lewin A, et al.Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma[J]. Am J Clin Oncol, 2005, 28(4): 359-366.
[7] Chaukar D, Prabash K, Rane P, et al.Prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery with neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer[J]. J Clin Oncol, 2022, 40(3): 272-281.
[8] Wang KX, Cui TY, Yang XD, et al.Study on efficacy and safety of low-dose apatinib combined with camrelizumab and SOX regimen as first-line treatment of locally advanced and unresectable gastric/gastroesophageal junction cancer: a protocol for an open-label, dose escalation and extension phase Ib clinical trial?[J].Onco Targets Ther, 2021, 14: 4859-4865.
[9] Yang G, Su X, Yang H, et al.Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma[J]. Ann Transl Med, 2021, 9(15): 1254-1265.
[10] Qiao ZY, Zhang ZJ, Lv ZC, et al.Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review[J]. Front Immunol, 2021, 12: 653437.
[11] Scott LJ.Apatinib: a review in advanced gastric cancer and other advanced cancers[J]. Drugs, 2018, 78(7): 747-758.
[12] Liao J, Jin H, Li S, et al.Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 454-462.
[13] Jia X, Wen Z, Sun Q, et al.Apatinib suppresses the proliferation and apoptosis of gastric cancer cells via the PI3K/Akt signaling pathway[J]. J BUON, 2019, 24(5): 1985-1991.
[14] Li J, Qin S, Xu J, et al.Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13): 1448-1454.
[15] Geng R, Song L, Li J, et al.The safety of apatinib for the treatment of gastric cancer[J]. Expert Opin Drug Saf, 2018, 17(11): 1145-1150.
[16] Zhao S, Ren S, Jiang T, et al.Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer[J]. Cancer Immunol Res, 2019, 7(4): 630-643.
[17] Xu J, Zhang Y, Jia R, et al.Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523.
[18] Lan C, Shen J, Wang Y, et al.Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2020, 38(34): 4095-4106.
[19] 赵灵颖, 张文青, 李存玺, 等. 阿帕替尼抗肿瘤作用机制研究进展[J]. 肿瘤防治研究, 2021, 48(1): 7-11.
Zhao LY, Zhang WQ, Li CX, et al.Research progress on antitumor mechanism of apatinib[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 7-11.
[20] 罗详冲, 李高峰. PD-1抑制剂卡瑞利珠单抗在晚期恶性肿瘤中的应用进展[J]. 解放军医学杂志, 2020, 45(6): 672-679.
Luo XC, Li GF.Application of PD-1 inhibitor camrelizumab in advanced malignancies[J]. Medical Journal of Chinese People's Liberation Army, 2020, 45(6): 672-679.
[21] Cai X, Wei B, Li L, et al.Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression[J]. Int Immunopharmacol, 2020, 88: 106858.
[22] Gebbia V, Mantovani G, Farris A, et al.Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase Ⅱ multicenter study[J]. Cancer, 1997, 79(7): 1394-1400.